GLP-1 is a useful example of what an emerging trend actually looks like. The science existed for decades before the investment opportunity became obvious. Exenatide was approved for diabetes in 2005, liraglutide for obesity in 2014, and semaglutide for diabetes in 2017. The real inflection came when efficacy got large enough to change behavior, and Wegovy’s approval for obesity in 2021 turned weight-loss drugs from a niche into a treatment category.
That was the transition from discovery to adoption, and we’re well beyond it. In the third quarter of 2026, Eli Lilly sold $10.7 billion of Mounjaro worldwide and $5.3 billion of Zepbound in the U.S. Together they were about two-thirds of Lilly’s revenue, which grew 39% from a year earlier. GLP-1 is now one of the largest growth engines in global pharmaceuticals.
But I don’t think the trend is mature. It’s entering its second act: mass adoption, product proliferation and expansion beyond weight loss. Four return drivers are carrying it.
Efficacy Created the Demand
Extraordinary efficacy created extraordinary demand. Semaglutide produced about 15% average weight loss in Novo Nordisk’s pivotal obesity trial, and tirzepatide pushed that to about 21%. In May, Lilly reported that its investigational retatrutide averaged 28.3% weight loss at 80 weeks on the highest dose in a Phase 3 obesity trial, with 45% of patients on that dose losing 30% or more. That’s territory historically associated with bariatric surgery, and it changes the addressable market. The comparison is no longer a drug versus diet and exercise. Increasingly, it’s a drug versus surgery, chronic disease progression and the economic cost of obesity.
Access Turns Demand Into Revenue
Demand doesn’t become revenue until someone pays for the drug, and payment has been the category’s tightest constraint. KFF’s 2026 employer survey found that only 18% of employers with 200 or more workers cover GLP-1s primarily for weight loss, and among employers with 5,000 or more workers, coverage fell from 43% to 33%. Medicare is moving the other way. Its GLP-1 Bridge, launched in July and running through 2027, gives eligible beneficiaries certain GLP-1 drugs for a $50 monthly copay.
Penetration can keep rising even as prices fall, so the economics come down to patients × years on therapy × net price. Broader reimbursement, new indications and global reach grow the patient count. Chronic use extends duration. Competition and payer pressure compress price.
Lilly’s third quarter shows that math at work. U.S. revenue rose 34% even though realized prices fell 7%. Outside the U.S., volume rose 76% while prices fell 29%, primarily because Mounjaro was added to China’s national reimbursement list. That’s reimbursement trading price for volume, and for now, volume is overwhelming price compression.
The Pill Widens the Market
An injectable obesity drug is one market. An effective pill is potentially a much larger one. Novo launched the Wegovy pill in January and reported more than 265,000 weekly U.S. prescriptions by mid-July, with roughly 80% of patients new to GLP-1s and most prescriptions paid out of pocket. Lilly followed in April with Foundayo, a small-molecule pill with no food or water restrictions. Oral delivery removes one of the remaining barriers to adoption and moves obesity treatment deeper into primary care, and eventually into a much larger consumer population.
From Obesity Drug to Cardiometabolic Platform
This is the driver I think the market still underappreciates: GLP-1 is becoming a cardiometabolic platform, not just an obesity category. Between them, semaglutide and tirzepatide already carry U.S. approvals beyond weight loss in cardiovascular risk reduction, kidney disease, sleep apnea and fatty liver disease. Lilly plans to file retatrutide in the first quarter of 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain. Novo is answering with amylin-based therapies: CagriSema, filed with the FDA last December, and zenagamtide, now in Phase 3.
That’s where the optionality is. The original thesis was that people would take these drugs to lose weight. The larger thesis may be that metabolic medicine becomes one of the dominant treatment platforms in healthcare. Those are very different addressable markets.
The Edge Has Moved Downstream
Recognizing the trend isn’t the edge anymore, because everyone recognizes GLP-1. The edge has moved downstream, to determining who captures the incremental economics as the category scales, and it won’t be every GLP-1 manufacturer or every company associated with obesity. Novo illustrates the problem. It helped build the category, yet CagriSema fell short of tirzepatide head to head, and even after raising its outlook in November, Novo expects 2026 adjusted sales to land between down 2% and up 2% at constant exchange rates, in the middle of the biggest demand boom the category has seen. A secular trend can be right while a specific investment is wrong.
So the next phase requires finding the relative winners inside the trend: the companies with the best efficacy, the easiest delivery, the manufacturing capacity to meet demand, payer access, the lowest cost per patient, indications competitors don’t have, and the next molecule rather than the last one. The early evidence already separates the two leaders. Lilly leads in injectable efficacy and scale, while Novo has the early lead in pills.
Then there’s a second layer: who benefits indirectly. If hundreds of millions of people eventually eat fewer calories, lose substantial weight and suffer fewer obesity-related diseases, GLP-1 changes demand across food, healthcare, medical devices, apparel, fitness, insurance and possibly surgical procedures. Some incumbents lose economics while entirely different businesses gain them. That’s where an Emerging Trends strategy differs from simply buying Lilly and Novo. It means mapping the entire economic chain and asking where the change in cash flows will be largest relative to what the market already expects.
Stage 3 of the Trend
I’d place GLP-1 in Stage 3 of an emerging-trend lifecycle: scaling and competitive expansion. Stage 1 was scientific discovery. Stage 2 was validation and early adoption. Stage 3 is where we are now, with enormous demand, rapidly expanding capacity, improving technology, broader reimbursement, multiple competitors and new indications. Stage 4 will eventually be commoditization and maturity, when penetration is high, efficacy differences narrow, pricing becomes the dominant battleground and abnormal returns migrate elsewhere.
We’re not there yet, but the opportunity has changed. The easy edge was recognizing that GLP-1 worked before everyone understood what it could become, and that edge is gone. The edge now is identifying where the next dollar of economic value created by GLP-1 will accrue before consensus fully prices it.
That’s what an ASYMMETRY® Emerging Trends strategy is built to do. We aren’t trying to discover something nobody has heard of. We’re trying to identify when a change becomes powerful enough to alter cash flows, determine who actually captures those cash flows, require the market to confirm our thesis, define the downside, size the risk, and stay with the trend while the expected payoff remains asymmetric.
